Apogee Therapeutics CEO Michael Henderson Executes $1.67 Million Stock Sale Under Pre-Arranged Plan
Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, Inc. (NASDAQ: APGE), executed a sale of common stock totaling approximately $1,667,621 on June 10, 2026. The transaction involved the disposition of 19,000 shares, with per-share prices ranging from $82.21 to $86.89. These sales were conducted under a Rule 10b5-1 trading plan…